EuroPCR 2019 | BASKET-SMALL 2: Drug-Coated Balloons vs. DES in Small Vessels

This angiographic substudy supports the safety of drug-coated balloons in small vessels. Despite better angiographic outcomes, there were eight cases of stent thrombosis among drug-eluting stent (DES) patients, while there was none with drug-coated balloons.

In patients with small vessels, using a drug-coated balloon appears safe and comparable to DES, with favorable angiographic outcomes at 1 year.

The main BASKET-SMALL 2 trial was conducted at 14 sites in Germany, Switzerland, and Austria. This trial had an open-label, noninferiority design, and it included 758 patients with de novo lesions in small vessels (at least 2 mm but less than 3 mm in diameter). All lesions were predilated, and absence of flow-limiting dissections and residual stenosis <30% were requirements for randomization.


Read also: EuroPCR 2019 | Intravascular Imaging Almost Indispensable for Planning an Angioplasty.


Patients were randomized to undergo angioplasty with the SeQuent Please paclitaxel-coated balloon (B. Braun Melsungen) or first- or second-generation DES. As regards DES, researchers initially used TAXUS and then Xience.

Patients in the drug-coated balloon group received dual antiplatelet therapy for 4 weeks, whereas the DES group received it for 6 weeks (yes, only 6) if they were stable or 1 year if they had acute coronary syndrome.

At 1 year, the rate of major adverse cardiac events (MACE) was 7.33% for the balloon group and 7.45% for the DES group. Such difference met criteria for noninferiority.


Read also: EuroPCR 2019 | TRILUMINATE: Tricuspid Repair with Clip Improves Regurgitation and Quality of Life.


This protocol could be criticized regarding the short duration of dual antiplatelet therapy for the DES group and stable chronic angina patients, particularly if we consider the initial use of a first-generation DES, TAXUS, with verified higher rates of thrombosis than new DES.

Original Title: Drug-coated balloons vs drug-eluting stents for the treatment of small coronary artery lesions: angiographic analysis from the randomized BASKET-SMALL 2 trial.

Presenter: Jeger R et al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...